Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H32N4O3 |
| Molecular Weight | 472.5787 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CN1CCCC1)OC2=CC=C3C=C2COC\C=C\COCC4=CC(=CC=C4)C5=CC=NC(N5)=N3
InChI
InChIKey=HWXVIOGONBBTBY-ONEGZZNKSA-N
InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
| Molecular Formula | C28H32N4O3 |
| Molecular Weight | 472.5787 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:23:15 UTC 2023
by
admin
on
Sat Dec 16 19:23:15 UTC 2023
|
| Record UNII |
G22N65IL3O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/10/767
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
||
|
FDA ORPHAN DRUG |
245607
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
||
|
NCI_THESAURUS |
C125450
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BC-48
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
DB11697
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
46216796
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
SUB114513
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
G22N65IL3O
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
2595243
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
DTXSID801045679
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
937272-79-2
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
G22N65IL3O
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
C78837
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
9385
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
100000142107
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | |||
|
EU/3/10/767(POSITIVE)
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY | On 25 August 2010, orphan designation (EU/3/10/767) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treatment of post-essential thrombocythaemia myelofibrosis. The sponsorship was transferred to Baxter Innovations GmbH, Austria, in March 2015. In May 2015, Baxter Innovations GmbH changed name to Baxalta Innovations GmbH. The sponsorship was transferred to CTI Life Sciences Ltd, United Kingdom, in November 2016. | ||
|
Pacritinib
Created by
admin on Sat Dec 16 19:23:18 UTC 2023 , Edited by admin on Sat Dec 16 19:23:18 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
OFF-TARGET->INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE LESS ACTIVE -> PARENT |
Predominant Metabolite in human studies
MAJOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA; URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
Major metabolite in animal species lesser metabolite in human studies. Has 50% of the activity of the parent
MAJOR
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
